In the past decade, immunotherapy has revolutionized cancer therapy. However, a significant proportion of patients still does not respond to immunotherapy. We have established and are currently extending a comprehensive bioregistry of patients undergoing checkpoint inhibitors (CPI) and other immunotherapeutic and targeted treatments. We perform a detailed immunologic work-up on a variety of tumor and lymphoma patients in our clinic. 

Our goal is the identification of potential biomarkers to predict therapy outcome, to study immunomodulation by these treatments and the occurrence of specific side effects, such as immune-related adverse events.